Exosens (EXENS.PA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-193.9%

-€50.85

vs €54.15 price

Levered DCF

€50.42

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

4.91

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	57.68×	32.38×	35.71×	54.05×	-4.08×	-38.46×
P/B	5.54×	2.39×	2.98×	3.32×	3.53×	6.26×
P/S	5.27×	2.5×	1.91×	3.03×	3.66×	4.06×
EV / EBITDA	18.85×	10.41×	11.61×	16.28×	-7.91×	28.17×
Gross margin	21.8%	57.2%	55.5%	56.8%	60.2%	61.3%
Operating margin	21.8%	19.5%	17.3%	15.2%	19.2%	20.5%
Net margin	9.1%	7.8%	5.4%	5.6%	-89.6%	-10.6%
Current ratio	2.46×	2.94×	1.75×	2×	2.11×	2.02×
Debt / equity	0.63×	0.63×	1.53×	1.39×	1.21×	4.65×
Interest coverage	7.41×	2.76×	1.8×	2.01×	0.85×	0.73×
Dividend yield	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	11.9%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	9.6%	7.4%	8.4%	6.1%	-86.6%	-16.3%
Return on invested capital	10.5%	7.9%	9.0%	4.3%	7.7%	5.5%
Return on assets	4.9%	3.8%	2.6%	2.1%	-32.3%	-2.6%
Free cash flow yield	2.0%	9.7%	3.2%	4.2%	3.8%	5.0%
Earnings yield	1.7%	3.1%	2.8%	1.8%	-24.5%	-2.6%
Enterprise value	€2.7B	€1.1B	€904.1M	€834.1M	€799.9M	€1B
Net debt / EBITDA	1.49×	1.33×	3.81×	4.42×	-1.9×	11.52×
Cash conversion cycle (days)	131	211	198	197	239	292